Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis

Journal of Experimental Medicine

Volumn 188, Issue 5, 1998, Pages 887-896

  Gao, Yakun ^a   Herndon, John M ^a   Zhang, Hui ^a   Griffith, Thomas S ^a   Ferguson, Thomas A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; FasL; Immune privilege; Inflammation; Interleukin 10

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 10;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLINDNESS; CELL DIFFERENTIATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTERIOR CHAMBER; ANTIGEN PRESENTATION; ANTIGENS, CD95; APOPTOSIS; CELL DIFFERENTIATION; FAS LIGAND PROTEIN; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-4; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; TH2 CELLS;

EID: 0032494144     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.5.887     Document Type: Article

References (47)

1. Kroemer, G. 1995. The pharmacology of T cell apoptosis. Adv. Immunol. 58:211-296.
2. Abbas, A.K. 1996. Die and let live. Eliminating dangerous lymphocytes. Cell. 84:655-657.
3. Martin, S.J., C.P.M. Reutelingsperger, A.J. McGahon, J.A. Rader, R. van Schie, D. LaFace, and D.R. Green. 1995. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of bcl-2 and abl. J. Exp. Med. 182:1545-1556.
4. Rivas, J.M., and S.E. Ullrich. 1992. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes: an essential role for keratinocyte-derived IL-10. J. Immunol. 149:3865-3871.
5. Griffith, T.S., X. Yu, J.M. Herndon, D.R. Green, and T.A. Ferguson. 1996. CD95-induced apoptosis ot lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 5:7-16.
6. Nagata, S., and P. Golstein. 1995. Fas the death factor. Science. 267:1449-1456.
7. Mogil, R.J., L. Radvanyi, R. Gonzalez-Quintial, R. Miller, G. Mills, A. Theofilopoulos, and D.R. Green. 1995. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis m vivo. Int. Immunol. 7:1451-1458.
8. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195-200.
9. Hahne, M., D. Rimoldi, P. Schroter, M. Romero, L. Schreier, P. French, T. Schneider, A. Bornand, D. Fontana, D. Leinard, et al. 1996. Melanoma cell expression of Fas (Apo-1, CD95) ligand: implications for tumor immune escape. Science. 274:1363-1366.
10. O'Connell, J., G.G. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counter attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-1082.
11. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
12. Hunt, J.S., D. Vassmer, T.A. Ferguson, and L. Miller. 1997. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J. Immunol. 158:4122-4128.
13. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630-632.
14. Stuart, P.M., T.S. Griffith, N. Usui, J.S. Pepose, X. Yu, and T.A. Ferguson. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:396-402.
15. Ferguson, T.A., J.C. Waldrep, and H.J. Kaplan. 1987. The immune response and the eye. II. The nature of T suppressor cell induction in anterior chamber associated immune deviation ACAID. J. Immunol. 139:352-357.
16. Ferguson, T.A, J. Hayashi, and H.J. Kaplan. 1989. The immune response and the eye. III. Anterior chamber associated immune deviation can be adoptively transferred by serum. J. Immunol. 143:821-826.
17. Ferguson, T. A., and T.S. Griffith. 1997. A vision of cell death: insights into immune privilege. Immunol. Rev. 156:167-184.
18. Kaplan, H.J., and J.W. Streilein. 1977. Immune response to immunization via the anterior chamber of the eye: I. F1-lymphocyte induced immune deviation. J. Immunol. 118:809-814.
19. Wilbanks, G., M. Mammolenti, and J.W. Streilein. 1991. Studies on the induction of anterior chamber-associated immune deviation ACAID. II. Eye-derived cells participate in generating blood-borne signals that induce ACAID. J. Immunol. 146:3018-3023.
20. Li, X.-Y., T. D'Orazio, and J.Y. Niederkorn. 1996. Role of Th1 and Th2 cell in anterior chamber associated immune deviation. Immunol. 89:34-40.
21. L and bcl-2 repress a common pathway of cell death. J. Exp. Med. 182:821-828.
22. Hsieh, C.-S., A.B. Heimberger, J.S. Gold, A. O'Garra, and K.M. Murphy. 1992. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an T-cell-receptor transgenic system. Proc. Natl. Acad. Sci. USA. 89: 6065-6069.
23. + T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:547-549.
24. Griffith, T.S., J.M. Herndon, J. Lima, M. Kahn, and T.A. Ferguson. 1995. The immune response and the eye. T-cell receptor α-chain related molecules regulate the systemic immunity to antigen presented via the anterior chamber of the eye. Int. Immunol. 7:1617-1625.
25. Ferguson, T.A., P. Dube, and T.S. Griffith. 1994. Regulation of contact hypersensitivity by interleukin 10. J. Exp. Med. 179:1597-1604.
26. Iwai, K., T. Miyawaki, T. Takizawa, A. Konno, K. Ohta, A. Yachie, H. Seki, and N. Taniguchi. 1994. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood. 4:1201-1208.
27. L. Immunity. 3:87-98.
28. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubl, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, and D.R. Green. 1995. Cell-autonomous Fas (CD95)/ Fas ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:441-444.
29. Ferguson, T.A., J.M. Herndon, and P. Dube. 1994. The immune response and the eye: a role for TNF in anterior chamber-associated immune deviation. Invest. Ophthalmol. Vis. Sci. 35:2643-2651.
30. Berg, D.J., M.W. Leach, R. Kuhn, K. Rajewsky, W. Muller, N.J. Davidson, and D. Rennick. 1995. Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses. J. Exp. Med. 182:99-108.
31. Sperline, A.I., and J.A. Bluestone. 1996. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 153: 155-182.
32. Nishigori, C., D.B. Yarosh, S.E. Ullrich, A.A. Vink, C.D. Bucana, L. Roza, and M.L. Kripke. 1996. Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes. Proc. Natl. Acad. Sci. USA. 93:10354-10359.
33. Leverkus, M., M. Yaar, and B.A. Gilchrest. 1997. Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes. Exp. Cell Res. 232:255-262.
34. + T cells undergoing apoptosis: a mechanism for T cell clearance during resolution of viral infections. J. Exp. Med. 180:1943-1947.
35. Kovacsivics-Bankowski, M., and K.L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267:243-246.
36. Voll, R.E., M. Herrmann, E.A. Roth, C. Stach, J.R. Kalden, and I. Girkontaite. 1997. Immunosuppressive effects of apoptotic cells. Nature. 390:350-351.
37. Van Hogezand, R.A., and H.W. Verspaget. 1997. New therapies for inflammatory bowel disease: an update on chimeric anti-TNFα antibodies and IL-10 therapy. Scand. J. Gastroenterol. Suppl. 223:105-107.
38. de Waal-Malefyt, R., J. Haanen, H. Spits, M.-G. Roncarolo, A. de Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J.E. de Vries. 1991. IL-10 and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II MHC expression. J. Exp. Med. 174:915-924.
39. Ding, L., P.S. Linsley, L.Y. Huang, R.N. Germain, and E.M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224-1231.
40. D'Andrea, A., M. Aste-Amezaga, N.M. Valiante, X. Ma, M. Kubin, and G. Trinchieri. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041-1048.
41. Murphy, E.E., G. Terres, S.E. Macatonia, C.S. Hsieh, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, and A. O'Garra. 1994. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180:223-231.
42. Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature. 383:787-793.
43. Fiorentino, D.F., A. Zlotnik, P. Vieira, T.R. Mosmann, M. Howard, K. Moore, and A. O'Garra. 1991. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146:3444-3450.
44. Kuchroo, V.K., M.P. Das, J.A. Brown, A.M. Ranger, S.S. Zamvil, R.A. Sobel, H.L. Wemer, N. Nabavi, and L.H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:707-718.
45. Macatonia, S.E., T.M. Doherty, S.C. Knight, and A. O'Garra. 1993. Differential effect of IL-10 on dendritic cell-induced T-cell proliferation and IFN-gamma production. J. Immunol. 150:3755-3765.
46. Rocken, M., M. Racke, and E.M. Shevach. 1996. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today. 17:225-231.
47. Bellone, M., G. Lezzi, P. Rovere, G. Galati, A. Ronchetti, M.P. Ptotti, J. Davoust, C. Rugarli, and A.A. Manfredi. 1997. Processing of engulfed apoptotic bodies yields T cell epitopes. J. Immunol. 159:5391-5399.